- Home
- MNOV vs AVTX Comparison
MNOV vs AVTX Comparison
Compare MNOV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- AVTX
- Stock Information
- Founded
- MNOV 2000
- AVTX 2011
- Country
- MNOV United States
- AVTX United States
- Employees
- MNOV N/A
- AVTX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- AVTX Health Care
- Exchange
- MNOV Nasdaq
- AVTX Nasdaq
- Market Cap
- MNOV 60.3M
- AVTX 248.3M
- IPO Year
- MNOV 2005
- AVTX 2015
- Fundamental
- Price
- MNOV $1.21
- AVTX $18.26
- Analyst Decision
- MNOV Strong Buy
- AVTX Strong Buy
- Analyst Count
- MNOV 2
- AVTX 9
- Target Price
- MNOV $7.00
- AVTX $30.14
- AVG Volume (30 Days)
- MNOV 29.2K
- AVTX 406.9K
- Earning Date
- MNOV 11-12-2025
- AVTX 11-07-2025
- Dividend Yield
- MNOV N/A
- AVTX N/A
- EPS Growth
- MNOV N/A
- AVTX N/A
- EPS
- MNOV N/A
- AVTX N/A
- Revenue
- MNOV $134,599.00
- AVTX $441,000.00
- Revenue This Year
- MNOV N/A
- AVTX N/A
- Revenue Next Year
- MNOV N/A
- AVTX N/A
- P/E Ratio
- MNOV N/A
- AVTX N/A
- Revenue Growth
- MNOV N/A
- AVTX N/A
- 52 Week Low
- MNOV $1.13
- AVTX $3.39
- 52 Week High
- MNOV $2.55
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- MNOV 41.59
- AVTX 69.82
- Support Level
- MNOV $1.19
- AVTX $16.77
- Resistance Level
- MNOV $1.23
- AVTX $19.01
- Average True Range (ATR)
- MNOV 0.02
- AVTX 1.46
- MACD
- MNOV -0.00
- AVTX 0.22
- Stochastic Oscillator
- MNOV 23.45
- AVTX 81.50
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).